Olav Chen是Storebrand 的基金管理人、挪威财经界的知名人物, 2009年9月1日被挪威主流媒体评为挪威最有才华的年轻领导者之一。他对全球宏观经济有着独到深入的见解，经常接受媒体采访，发表对当下财经热点的看法。Olav Chen的演讲着重于回顾总结全球经济、当前状态以及对未来的展望，并结合个人理财投资进行分析。他认为低风险高回报是不现实的，建议每个人要了解自己的风险偏好，并根据自己的承受能力合理决定资产配置。
Olav Chen介绍到Storebrand有着一套科学的资产配置决策和调整机制，比如在2008年金融风暴到来之前他们将大量的股票抛掉，变换成现金存入银行。他的核心职责就是决定6000亿挪威克朗资产的养老金将如何在股票、固定收益、房地产等资产类别中进行配置并且得到安全回报。对地区经济、行业发展的分析也是他的工作重点。Olav 还着重分析了当下宽松的货币政策虽然没有造成严重的通货膨胀，却在很大程度上拉高了资产价格，例如股票和房地产。他认为这样造成了一定程度的资产价格下行风险，尤其是当下美联储的加息预期明显，其他国家的央行也极有可能在美国加息后跟进。由于时间所限，Olav留给大家一个问题作思考：当欧洲、挪威中央银行加息的时候，房地产和股票价格的波动将会如何呢?
Olav 的演讲驾轻就熟，演讲过程中不断与听众互动，使会场气氛默契而活跃。大家既问到了他对当前股票价格水平、系统性风险的看法，也问到了Storebrand采用怎样的分析工具取得优于市场的回报率以及风险管理模式等等，他都游刃有余地与大家分享了他的见解和观点。
北欧绿色邮报网报道（记者陈雪霏）– 2016年12月5日，美国血液学会（ASH）在美国圣地亚哥颁发了本届欧尼斯特•博特勒奖，获奖人员为来自上海交通大学附属瑞金医院上海血液学研究所的陈竺教授，以及巴黎圣路易医院的Hugues de Thé 教授。ASH将此奖授予陈竺，源于他的团队在治疗急性早幼粒细胞白血病（APL）上的贡献。这曾是一种极为凶险，死亡率很高的恶性血液疾病。
Stockholm, Feb. 6 (Greenpost)–The Royal Swedish Academy of Sciences has decided to award the Sjöberg Prize 2018 to
Zhu Chen, Shanghai Jiao Tong University, China,Anne Dejean, Institut Pasteur and Inserm, Paris, France andHugues de Thé, Collège de France, Paris, France“for the clarification of molecular mechanisms and the development of a revolutionary treatment for acute promyelocytic leukaemia.”
The Sjöberg Prize 2018, worth one million US dollars, is awarded to cancer researchers Zhu Chen, Anne Dejean and Hugues de Thé. They have succeeded in curing one of the deadliest forms of cancer using a unique treatment method that is based on arsenic and retinoic acid. This method shows how cancer treatment is becoming more targeted as we learn more about the mechanisms responsible for the disease.
The Royal Swedish Academy of Sciences has decided to award the Sjöberg Prize 2018 toZhu Chen, Shanghai Jiao Tong University, China,Anne Dejean, Institut Pasteur and Inserm, Paris, France andHugues de Thé, Collège de France, Paris, France“for the clarification of molecular mechanisms and the development of a revolutionary treatment for acute promyelocytic leukaemia.”Using the treatments available in the 1980s, more than 75 per cent of patients with acute promyelocytic leukaemia died within two years. With the current treatment, nine out of ten patients are cured. Illustration: Mattias Karlén, the Royal Swedish Academy of Sciences.
This year’s Sjöberg Laureates have developed a new and targeted treatment for a specific form of blood cancer called acute promyelocytic leukaemia. It was once one of the deadliest forms of cancer, but it is now possible to cure nine out of ten patients who receive the new treatment.
The treatment is unique because it is the first standard treatment for acute leukaemia that does not include chemotherapy. Instead, a combination treatment is used, which consists of a form of vitamin A, “all-trans retinoic acid”, also called ATRA, along with arsenic trioxide.
The idea of using arsenic comes from traditional medicine, but this method has been scientifically tested and proven in this form. The Laureates have made this revolutionary development possible by methodically mapping the molecular mechanisms responsible for the disease. By identifying a specific genetic mutation and aiding the destruction of a faulty protein in specific cells, it was possible to stop the process that resulted in death for three out of four patients. This treatment means the cancer cells disappear because they lose the ability to renew themselves.
These discoveries have been made in stages since the 1980s, and the treatment’s effects have been confirmed in numerous scientific studies. In many countries, this treatment combination is now the first choice of treatment for acute promyelocytic leukaemia.
The three Laureates remain very active in the field of cancer research. Anne Dejean now primarily dedicates her research to continuing her studies of liver cancer, and to investigating the significance of protein modification in how cancer develops. Hugues de Thé is interested in the potential for producing treatment methods for cancer that combine stimulating the cancer cells’ maturation and blocking their ability to renew themselves, while Zhu Chen is investigating genetic and molecular changes in other forms of leukaemia.
The hope is that the Sjöberg Prize, which mainly comprises research funding, will pave the way for further progress, leading to cures for more forms of cancer.
“It is really a great honour for me to share with Dr. de Thé and Dr. Dejean the prestigious 2018 Sjöberg Prize, which recognises important contributions to cancer research,” says Professor Zhu Chen, Shanghai Jiao Tong University.
“This prize means not only the glory, but even more importantly a responsibility, a responsibility for me, my team and our collaborators to continue efforts in the understanding of disease mechanisms of other types of haematological malignancies and to develop innovative, effective therapeutic strategies against those diseases through collaboration with other partners,” Professor Zhu Chen concludes.
Anne Dejean, Professor at Institut Pasteur and Research Director at Inserm, comments on the Prize:
“I feel deeply honoured and, at the same time, very privileged to join the company of the prior recipients, whom I hold in great esteem.”
“This is a wonderful recognition of our contribution to the understanding of the molecular and cellular basis for a severe form of leukemia and its efficient cure, that will foster future development of highly effective oncogene-targeted therapies founded on similar approaches.”
Hugues de Thé, Professor at Collège de France:
“This is the recognition of thirty years of work that ends up in daily clinical practice, as well as more than twenty years of tight collaboration and friendship with the Chinese group.
“This prize also recognizes a certain vision of medicine, shared with Zhu Chen, that is based on curiosity and goes from clinical observations, uncompromising basic science and feedback, to patient care. Freedom to search is one of the founding values of Collège de France, my home institution.”
The Laureates
Zhu Chen, Professor at Shanghai Jiao Tong University, China, Ph.D. in 1989 from Saint-Louis Hospital, Paris Diderot University, France. Born in 1953 in Shanghai, China. Zhu Chen, Shanghai Jiao Tong University
Anne Dejean, Professor at Institut Pasteur and Research Director at Inserm, Paris, France, Ph.D. in 1983 from Institut Pasteur, Paris, France. Born in 1957 in Cholet, France. Anne Dejean, Institut Pasteur
Hugues de Thé, Professor at Collège de France, Paris, France, Ph.D. in 1989 from Université Paris VI, France. Born in 1959 in Marseille, France. Hugues de Thé, Collège de France
Further information about the prize
The prize is awarded by the Royal Swedish Academy of Sciences and funded by the Sjöberg Foundation. The foundation was founded in 2016 by businessman Bengt Sjöberg, who donated two billion Swedish krona for the purpose of promoting scientific research that focuses on cancer, health and the environment.
